Feasibility and acceptability of a proposed pharmacy-based harm reduction intervention to reduce opioid overdose, HIV and hepatitis C
Name:
1-s2.0-S1551741119301639-main.pdf
Size:
2.661Mb
Format:
PDF
Description:
Final Published Version
Author
Meyerson, B EAgley, J D
Jayawardene, W
Eldridge, L A
Arora, P
Smith, C
Vadiei, N
Kennedy, A
Moehling, T
Affiliation
Univ Arizona, Coll PharmUniv Arizona, Southwest Inst Res Women
Issue Date
2020-05Keywords
Consolidated framework for implementation researchHIV
Harm reduction
hepatitis C
Naloxone access
Opioid overdose reduction
Pharmacy practice
Syringe access
Metadata
Show full item recordPublisher
ELSEVIER SCIENCE INCCitation
Meyerson, B. E., Agley, J. D., Jayawardene, W., Eldridge, L. A., Arora, P., Smith, C., ... & PharmNet Research Team. (2019). Feasibility and acceptability of a proposed pharmacy-based harm reduction intervention to reduce opioid overdose, HIV and hepatitis C. Research in Social and Administrative Pharmacy. https://doi.org/10.1016/j.sapharm.2019.08.026Rights
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Background: Evidence-based harm reduction intervention components which might benefit pharmacy patients have not been integrated and studied. Objective: To investigate the feasibility and acceptability of a proposed pharmacy-based harm reduction intervention to reduce opioid overdose, HIV and hepatitis C called PharmNet. Methods: Indiana managing pharmacists were surveyed in 2018 to assess the feasibility and acceptability of an intervention for opioid misuse screening, brief intervention, syringe and naloxone dispensing, and referrals provision. The Consolidated Framework for Implementation Research informed the survey development and analysis. Results: The sample included 303 (30.8%) pharmacists; 215 (70.9%) provided detailed written comments. Intervention Characteristics: 83.3% believed PharmNet would benefit patients, and that staff could deliver the intervention with adequate training (70.0%). Inner Setting: While 77.2% believed their pharmacy culture supported practice change, 57.5% of chain pharmacists believed their pharmacies would not have time for PharmNet. Outer Setting: 73.3% believed additional addiction and overdose screening is needed in their community, and pharmacies should offer new services to help reduce opioid overdose and addiction among their patients (79.5%). A vast majority (97.7%) were asked by patients in the past 2 years about syringe related issues; 67.7% were asked about syringes for non-prescription injection drug use. Individuals Involved: While 62.4% believed PharmNet was within pharmacy scope of practice and 90.1% were comfortable consulting about syringe use, pharmacists reported that they had limited control over the implementation environment. Process: 38.0% of pharmacists indicated interest in advising the development of PharmNet. Conclusions: An implementation trial of a modified version of PharmNet is likely feasible; yet will be challenged by structural pressures particularly in chain pharmacies. Successful implementation will involve the development of resources and policy components to manage outer and inner setting characteristics and align the intervention to the implementation environment.Note
Open access articleISSN
1551-7411EISSN
1934-8150PubMed ID
31611071Version
Final published versionae974a485f413a2113503eed53cd6c53
10.1016/j.sapharm.2019.08.026
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
Related articles
- Pilot implementation of the PharmNet naloxone program in an independent pharmacy.
- Authors: Eldridge LA, Meyerson BE, Agley J
- Issue date: 2023 Jan-Feb
- The PharmNet Harm Reduction Intervention for Community Pharmacies: Protocol for a Pilot Randomized Controlled Trial.
- Authors: Eldridge LA, Agley J, Meyerson BE, Golzarri-Arroyo L
- Issue date: 2022 Oct 24
- Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015.
- Authors: Stopka TJ, Donahue A, Hutcheson M, Green TC
- Issue date: 2017 Mar-Apr
- Impact of a statewide community pharmacy approach to opioid harm reduction.
- Authors: Sexton SM, Marciniak MW, Gatton O, Shelton P
- Issue date: 2023 Jan-Feb
- Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol.
- Authors: Nielsen S, Kowalski M, Wood P, Larney S, Bruno R, Shanahan M, Lenton S, Dietze P, Green T, Murnion B, Ritter A
- Issue date: 2019 Aug